Hypokalaemic and electrocardiographic effects of aminophylline and salbutamol in obstructive airways disease. 1987

J Crane, and C D Burgess, and A N Graham, and T J Maling
Department of Medicine, Wellington School of Medicine.

The hypokalaemic and electrocardiographic effects of nebulised salbutamol (2.35 mg x 2, 120 min apart) and intravenous aminophylline (6 mg/kg followed by 0.5 mg/kg/hr infusion) alone and in combination, were investigated in eight patients with stable asthma. Both agents produced significant hypokalaemia, mean maximum for salbutamol 0.55 mmol/l, mean maximum for aminophylline 0.29 mmol/l. Salbutamol increased the QTc interval and depressed T-wave amplitude whilst aminophylline decreased PR interval. These effects were increased when they were given in combination but were highly variable between individuals. It is likely that arrhythmias may be precipitated in patients with hypoxaemia, acidosis or those with preexisting cardiovascular disease.

UI MeSH Term Description Entries
D007008 Hypokalemia Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed) Hypopotassemia,Hypokalemias,Hypopotassemias
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008173 Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent. Obstructive Lung Diseases,Obstructive Pulmonary Diseases,Lung Disease, Obstructive,Obstructive Lung Disease,Obstructive Pulmonary Disease,Pulmonary Disease, Obstructive,Pulmonary Diseases, Obstructive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead

Related Publications

J Crane, and C D Burgess, and A N Graham, and T J Maling
April 1980, British journal of clinical pharmacology,
J Crane, and C D Burgess, and A N Graham, and T J Maling
December 1988, The American review of respiratory disease,
J Crane, and C D Burgess, and A N Graham, and T J Maling
March 1971, Postgraduate medical journal,
J Crane, and C D Burgess, and A N Graham, and T J Maling
August 1991, Postgraduate medical journal,
J Crane, and C D Burgess, and A N Graham, and T J Maling
May 2011, Expert opinion on pharmacotherapy,
J Crane, and C D Burgess, and A N Graham, and T J Maling
September 1989, Thorax,
J Crane, and C D Burgess, and A N Graham, and T J Maling
January 1989, The Journal of international medical research,
J Crane, and C D Burgess, and A N Graham, and T J Maling
February 1967, Circulation,
J Crane, and C D Burgess, and A N Graham, and T J Maling
January 1991, European journal of clinical pharmacology,
J Crane, and C D Burgess, and A N Graham, and T J Maling
December 1990, Lancet (London, England),
Copied contents to your clipboard!